[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Piccinin MR, Almeida JA Jr, Aydos RD, Nogueira DC, Silva RF: [Choroid metastasis of testicular primary site: case report]. Arq Bras Oftalmol; 2006 Nov-Dec;69(6):949-53
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Choroid metastasis of testicular primary site: case report].
  • [Transliterated title] Metástases de coróide de origem testicular: relato de caso.
  • Description of a male patient case, 22 years old, presenting visual acuity decrease in the left eye associated with the diagnosis of metastatic testicular tumor to lung and kidney.
  • Evaluation of the evolution of a choroid lesion compatible with ocular metastasis of testis tumor through ophthalmologic and echographic examinations.
  • There was resolution of the intraocular lesion together with lung radiologic improvement after chemotherapy during approximately 4 months of follow-up.
  • In spite of the remission of the ocular lesion, the patient died due to complications of cerebral metastasis.
  • Approached in the literature as rare, no report was found of a case of choroidal metastasis of a testicular site, this being, perhaps, its first description.
  • [MeSH-major] Choroid Neoplasms / secondary. Seminoma / secondary. Testicular Neoplasms
  • [MeSH-minor] Adult. Brain Neoplasms / secondary. Fatal Outcome. Humans. Lung Neoplasms / secondary. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17273696.001).
  • [ISSN] 0004-2749
  • [Journal-full-title] Arquivos brasileiros de oftalmologia
  • [ISO-abbreviation] Arq Bras Oftalmol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


2. George B, Wirostko WJ, Connor TB, Choong NW: Complete and durable response of choroid metastasis from non-small cell lung cancer with systemic bevacizumab and chemotherapy. J Thorac Oncol; 2009 May;4(5):661-2
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete and durable response of choroid metastasis from non-small cell lung cancer with systemic bevacizumab and chemotherapy.
  • Ocular metastasis from lung cancer is uncommon.
  • We report a patient with metastatic non-small cell lung cancer who was found to have a metastatic lesion in the choroid at the time of presentation.
  • After three cycles of chemotherapy, radiologic imaging and ophthalmologic examination demonstrated complete resolution of the choroid lesion.
  • This case report demonstrates the durable response of choroidal metastasis from non-small cell lung cancer to systemic bevacizumab and chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Choroid Neoplasms / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Carboplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19395911.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


3. Terakawa T, Miyake H, Muramaki M, Takenaka A, Fujisawa M: Salvage chemotherapy with methotrexate, etoposide and actinomycin D in men with metastatic nonseminomatous germ cell tumors with a choriocarcinoma component: a preliminary report. Int J Urol; 2010 Oct;17(10):881-5
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with methotrexate, etoposide and actinomycin D in men with metastatic nonseminomatous germ cell tumors with a choriocarcinoma component: a preliminary report.
  • The objective of the present study was to assess the use of salvage chemotherapy using methotrexate, etoposide and actinomycin D (MEA) in men with nonseminomatous germ cell tumor (NSGCT) with a choriocarcinoma component.
  • However, they failed to achieve the normalization of ß-human chorionic gonadotropin (ß-HCG).
  • Therefore, MEA therapy (methotrexate: 450 mg/body on day 1, actinomycin D: 0.5 mg/body on days 1–5, etoposide: 100 mg/body on days 1–5) was subsequently administered.
  • After MEA therapy (median: 3 cycles), serum ß-HCG was normalized in five of the nine patients.
  • Of these five, three achieved long-term disease-free survival and one died of disease unrelated to NSGCT, whereas the remaining patient developed disease recurrence and died of disease progression.
  • All four patients who failed to achieve the normalization of ß-HCG died of disease progression.
  • Although several severe toxicities greater than grade 3, which were mainly associated with bone marrow suppression, occurred in all patients, there was no treatment-related death.
  • Considering the current outcomes, MEA regimen could be an attractive option as a salvage chemotherapy for metastatic NSGCT patients with a choriocarcinoma component showing resistance to intensive conventional chemotherapies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / secondary. Salvage Therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Choriocarcinoma / blood. Choriocarcinoma / drug therapy. Choriocarcinoma / secondary. Chorionic Gonadotropin / blood. Choroid Neoplasms / secondary. Dactinomycin / administration & dosage. Etoposide / administration & dosage. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Methotrexate / administration & dosage. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20731738.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 1CC1JFE158 / Dactinomycin; 6PLQ3CP4P3 / Etoposide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


Advertisement
4. Kim KB, Bedikian AY, Camacho LH, Papadopoulos NE, McCullough C: A phase II trial of arsenic trioxide in patients with metastatic melanoma. Cancer; 2005 Oct 15;104(8):1687-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of arsenic trioxide in patients with metastatic melanoma.
  • METHODS: Twenty patients, 10 with metastatic melanoma of cutaneous origin and 10 with metastatic melanoma of choroidal origin, received arsenic trioxide 0.25 mg/kg/day for 5 days, followed by a maintenance dose of 0.35 mg/kg/day twice a week.
  • All patients with melanoma of cutaneous origin and four patients with melanoma of choroidal origin had received prior therapy.
  • Eight patients (five with melanoma of cutaneous origin, and three with melanoma of choroidal origin) had disease stabilization for at least six weeks.
  • The median overall survival duration for patients with melanoma of cutaneous origin was 7.9 months, and that of patients with melanoma of choroidal origin has not been reached at a median follow-up duration of 11.8 months.
  • CONCLUSIONS: Single-agent arsenic trioxide was generally well tolerated; however, no tumor regression was observed in this patient population.
  • Future clinical trials should evaluate arsenic trioxide in combination with other anticancer drugs that may improve its clinical activity in melanoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Choroid Neoplasms / drug therapy. Melanoma / drug therapy. Oxides / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society
  • (PMID = 16130126.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


5. De Potter P, Disneur D, Levecq L, Snyers B: [Ocular manifestations of cancer]. J Fr Ophtalmol; 2002 Feb;25(2):194-202
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ocular manifestations of cancer].
  • [Transliterated title] Manifestations oculaires des cancers.
  • Cancer may affect the eye and orbit as a direct result of metastatic neoplastic infiltration, compression, or circulating antibodies involving paraneoplastic retinal degeneration.
  • A metastatic tumor to the uvea is the most common form of an intraocular metastatic process.
  • The choroid is the most common site for uveal metastasis; metastases to the ciliary body, iris, retina, optic disk, and vitreous are rare.
  • Approximately one-third of patients have no history of primary cancer at the time of ocular diagnosis.
  • The short-term prognosis for vision is usually good after an individualized therapeutic approach (chemotherapy, hormonal therapy, external beam radiotherapy, or plaque radiotherapy), but the systemic prognosis is poor.
  • Identification of circulating antibodies against retinal proteins (recovering, 23-kDa retinal protein; 46-kDa and 60-kDa retinal proteins) serves to recognize the paraneoplastic nature of the patient's symptoms, which frequently develop before the cancer is diagnosed.
  • Anecdotal therapeutic responses are described after systemic steroids, immunoglobulin injection, and plasmapheresis.
  • Recognition of their visual symptoms and ocular findings should alert the ophthalmologist to the possibility of cancer and systemic evaluation should be pursued.
  • [MeSH-major] Eye Neoplasms / secondary. Lymphoma / diagnosis. Paraneoplastic Syndromes
  • [MeSH-minor] Adult. Child. Choroid Neoplasms / diagnosis. Choroid Neoplasms / secondary. Diagnosis, Differential. Eyelid Neoplasms / diagnosis. Eyelid Neoplasms / secondary. Female. Humans. Iris Neoplasms / diagnosis. Iris Neoplasms / secondary. Lymphoma, Non-Hodgkin / diagnosis. Male. Melanoma / complications. Melanoma / diagnosis. Melanoma / secondary. Orbital Neoplasms / diagnosis. Orbital Neoplasms / secondary. Prognosis. Retinal Diseases / etiology. Retinal Neoplasms / diagnosis. Retinal Neoplasms / secondary. Visual Acuity. Vitreous Body

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11941243.001).
  • [ISSN] 0181-5512
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 103
  •  go-up   go-down


6. Barbón JJ, González-Tuero J, Gay LL, Pérez-García FJ, Sampedro A: [Regression of a choroidal metastasis from prostate adenocarcinoma after hormonal therapy]. Arch Soc Esp Oftalmol; 2007 Nov;82(11):715-7
Hazardous Substances Data Bank. BICALUTAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Regression of a choroidal metastasis from prostate adenocarcinoma after hormonal therapy].
  • [Transliterated title] Regresión de una metástasis coroidea de adenocarcinoma de próstata con tratamiento hormonal.
  • CASE REPORT: We report a case of a patient diagnosed with prostatic adenocarcinoma with multiple bone metastases and a choroidal metastasis in his left eye.
  • Hormonal therapy with an anti-androgen and a LH-RH agonist was followed by regression of the choroidal mass over a period of 2 months.
  • No metastatic recurrence has been demonstrated after a follow-up period of 14 months.
  • DISCUSSION: Complete resolution of choroidal metastases of prostatic adenocarcinoma with hormonal therapy is exceptional, but the effect of this treatment on such metastases should be observed before recommending radiation therapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Androgen Antagonists / therapeutic use. Anilides / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Choroid Neoplasms / secondary. Nitriles / therapeutic use. Prostatic Neoplasms / drug therapy. Tosyl Compounds / therapeutic use
  • [MeSH-minor] Aged. Biopsy. Bone Neoplasms / secondary. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Prostate / pathology. Prostate-Specific Antigen / blood. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17979041.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Tosyl Compounds; A0Z3NAU9DP / bicalutamide; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


7. ElMallah MK, Chernoff AM, Blair NP: Testicular mixed germ-cell tumor metastatic to the choroid. Retin Cases Brief Rep; 2008;2(2):172-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular mixed germ-cell tumor metastatic to the choroid.
  • PURPOSE: To describe the fundus findings, ultrasonography, and fluorescein angiography of a testicular mixed germ-cell tumor metastatic to the choroid and to report prompt resolution of the choroidal lesion with systemic chemotherapy.
  • A 21-year-old man presented with a 10-cm testicular tumor.
  • Ophthalmic examination revealed a large, dome-shaped choroidal lesion in the left eye, filling the entire superotemporal quadrant and extending into the macula.
  • RESULTS: On ophthalmic examination 6 weeks after initiation of chemotherapy, the choroidal lesion had completely resolved, leaving only pigmentary changes.
  • Final ophthalmology follow-up 8 months after presentation demonstrated no recurrence of choroidal metastases.
  • CONCLUSION: Testicular germ-cell tumors have now been well described to metastasize to the choroid.
  • These choroidal metastases can show a prompt, favorable response to chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25389834.001).
  • [ISSN] 1935-1089
  • [Journal-full-title] Retinal cases & brief reports
  • [ISO-abbreviation] Retin Cases Brief Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Sari R, Camci C, Kutlu R, Totan Y, Sevinc A, Buyukberber S: The efficacy of acetazolamide on visual functions in a patient with choroid metastasis of breast carcinoma. Int J Clin Pract; 2001 Sep;55(7):488-90
Hazardous Substances Data Bank. ACETAZOLAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of acetazolamide on visual functions in a patient with choroid metastasis of breast carcinoma.
  • Breast carcinoma is the most frequent cancer in women and is the second leading cause of death.
  • Choroid metastasis of breast carcinoma can be found either at presentation or in remission.
  • It is frequently encountered in disseminated breast cancer with multiple organ metastasis.
  • It has been proposed that the oedema-reducing effect of acetazolamide is due to stimulated ion and fluid removal from the retina to the choroid.
  • A 40-year-old female patient on adjuvant chemotherapy for breast cancer was found to have an isolated choroid metastasis.
  • Clinical and radiological remission was achieved after orbital radiotherapy, chemotherapy and acetazolamide treatment.
  • In this case report, we emphasise the possible beneficial effect of acetazolamide in patients with choroid metastasis.
  • [MeSH-major] Acetazolamide / therapeutic use. Breast Neoplasms. Carbonic Anhydrase Inhibitors / therapeutic use. Carcinoma, Ductal, Breast / secondary. Choroid Neoplasms / secondary. Vision Disorders / drug therapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11594263.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carbonic Anhydrase Inhibitors; O3FX965V0I / Acetazolamide
  •  go-up   go-down


9. Lafay-Cousin L, Mabbott DJ, Halliday W, Taylor MD, Tabori U, Kamaly-Asl ID, Kulkarni AV, Bartels U, Greenberg M, Bouffet E: Use of ifosfamide, carboplatin, and etoposide chemotherapy in choroid plexus carcinoma. J Neurosurg Pediatr; 2010 Jun;5(6):615-21
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of ifosfamide, carboplatin, and etoposide chemotherapy in choroid plexus carcinoma.
  • OBJECT: Choroid plexus carcinomas (CPCs) are rare pediatric tumors with a generally poor prognosis.
  • Although the role of surgery is well recognized, the role of adjuvant chemotherapy and radiation therapy remains unclear.
  • In this paper, the authors' goal was to assess the role of second-look surgery and neoadjuvant ifosfamide, carboplatin, etoposide (ICE) chemotherapy in the management of CPC and to study neurocognitive outcome.
  • The median age at diagnosis was 18.6 months (range 1.1-65.3 months).
  • Four patients had evidence of metastatic disease at diagnosis.
  • Two of the 14 patients underwent gross-total resection during initial surgery; 12 of the patients received neoadjuvant chemotherapy, 10 of whom underwent second surgery.
  • In total, of 12 patients who received chemotherapy with a curative intent, 11 underwent a greater than 95% resection.
  • Neoadjuvant ICE chemotherapy was given prior to second surgery (median 4 cycles, range 2-5 cycles) and was continued after second resection for a median total of 7 cycles (range 4-16 cycles).
  • RESULTS: No tumor progression was observed during chemotherapy prior to second surgery.
  • Five patients subsequently experienced tumor progression/relapse.
  • None of the survivors received radiation therapy.
  • CONCLUSIONS: In this experience, second surgery following neoadjuvant ICE chemotherapy led to a high rate of complete or near-complete resection.
  • Chemotherapy appears to facilitate second-look surgery, in particular through a reduction of intraoperative blood loss.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Choroid Plexus Neoplasms / drug therapy. Choroid Plexus Neoplasms / surgery. Neoadjuvant Therapy
  • [MeSH-minor] Brain Damage, Chronic / etiology. Carboplatin / administration & dosage. Child, Preschool. Cognition Disorders / etiology. Drug Administration Schedule. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Infant. Kaplan-Meier Estimate. Male. Postoperative Complications / etiology. Reoperation. Retrospective Studies

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20515336.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide; ICE protocol 3
  •  go-up   go-down


10. Ino K, Mitsui T, Nomura S, Kikkawa F, Mizutani S: Complete remission of gestational choriocarcinoma with choroidal metastasis treated with systemic chemotherapy alone: case report and review of literature. Gynecol Oncol; 2001 Dec;83(3):601-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of gestational choriocarcinoma with choroidal metastasis treated with systemic chemotherapy alone: case report and review of literature.
  • BACKGROUND: Gestational choriocarcinoma is a malignant tumor that frequently metastasizes to the highly vascularized organs such as the lung, brain, and liver via hematogenous spread.
  • However, this tumor rarely metastasizes to the eye and only a few cases of metastasis to the choroid have been reported.
  • Ophthalmologic evaluation revealed a metastatic choroidal tumor, and a CT scan showed a metastatic tumor in the left lung.
  • A clinical diagnosis of metastatic gestational choriocarcinoma involving the choroid and lung was made.
  • The patient received 13 courses of combination chemotherapy, resulting in complete remission.
  • Radiotherapy and surgical treatment were unnecessary.
  • CONCLUSION: This is a very rare case of the successful treatment of gestational choriocarcinoma metastatic to the choroid using systemic chemotherapy alone.
  • [MeSH-major] Choriocarcinoma / drug therapy. Choriocarcinoma / secondary. Choroid Neoplasms / drug therapy. Choroid Neoplasms / secondary. Uterine Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2001 Elsevier Science.
  • (PMID = 11733980.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


11. Haritoglou C, Mueller AJ: [Regression of an uveal metastatic tumor from breast cancer during chemotherapy--a case report]. Ophthalmologe; 2003 Apr;100(4):326-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Regression of an uveal metastatic tumor from breast cancer during chemotherapy--a case report].
  • [Transliterated title] Visusanstieg nach Chemotherapie einer Aderhautmetastase eines Mammakarzinoms.
  • BACKGROUND: Choroidal metastases generally respond well to radiation treatment.
  • In these cases, alternatives to radiation, which is a palliative treatment in most cases anyway, should be considered.
  • MATERIAL AND METHODS: We present the clinical and echographic findings of a case of a 39-year-old patient with choroidal metastasis from breast carcinoma.
  • RESULTS: We observed a regression of the metastasis and an improvement of visual acuity from 0.2 to 1.0 under systemic chemotherapy.
  • Echography showed a decrease of tumor height and increasing reflectivity indicating progressive scarring of the lesion.
  • Up to now, the patient has survived 9 years after initial diagnosis.
  • CONCLUSIONS: Especially in cases in which a deterioration of visual acuity after radiation must be expected, the follow-up during systemic chemotherapy alone might be considered an alternative option, as it not only might preserve vision, but also allows an "in vivo" monitoring of the success of the chemotherapy applied.
  • [MeSH-major] Breast Neoplasms. Choroid Neoplasms / secondary. Paclitaxel / analogs & derivatives. Taxoids
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / therapeutic use. Combined Modality Therapy. Diphosphonates / administration & dosage. Diphosphonates / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Fluorescein Angiography. Follow-Up Studies. Humans. Tamoxifen / administration & dosage. Tamoxifen / therapeutic use. Time Factors. Visual Acuity

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12682767.001).
  • [ISSN] 0941-293X
  • [Journal-full-title] Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
  • [ISO-abbreviation] Ophthalmologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 0 / Diphosphonates; 0 / Taxoids; 094ZI81Y45 / Tamoxifen; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; OYY3447OMC / pamidronate; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


12. Jennings MT, Cmelak A, Johnson MD, Moots PL, Pais R, Shyr Y: Differential responsiveness among "high risk" pediatric brain tumors in a pilot study of dose-intensive induction chemotherapy. Pediatr Blood Cancer; 2004 Jul;43(1):46-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential responsiveness among "high risk" pediatric brain tumors in a pilot study of dose-intensive induction chemotherapy.
  • BACKGROUND: These factors have been predictive for progressive disease on therapy (PDOT) among pediatric brain tumors: >1.5 cm(2) unresectable tumor, glioblastoma, supratentorial primitive neuroectodermal tumor, and metastatic medulloblastoma (MBL).
  • Maintenance chemotherapy consisted of eight cycles of carboplatin, etoposide, and vincristine.
  • RESULTS: Twenty newly diagnosed patients [nine primitive neuroectodermal tumors/MBL, one choroid plexus carcinoma, eight malignant gliomas, and two anaplastic ependymomas] were treated.
  • Induction chemotherapy produced partial and minor responses (MRs) among 5/10.
  • Expression of the biologic factors was similar between both groups and did not correlate with diagnosis or response.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Neuroectodermal Tumors, Primitive / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Dose Fractionation. Etoposide / administration & dosage. Female. Humans. Male. Neoadjuvant Therapy. Pilot Projects. Statistics, Nonparametric. Survival Rate. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15170889.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Venkatesh P, Garg S: Regression of choroidal metastasis from breast carcinoma following Letrozole therapy. Clin Exp Ophthalmol; 2007 Jul;35(5):492-4
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of choroidal metastasis from breast carcinoma following Letrozole therapy.
  • Metastasis to the choroid from primary tumours elsewhere in the body is not an infrequent occurrence.
  • Management of such metastasis may involve modalities such as radiotherapy, chemotherapy, photocoagulation and surgical resection.
  • The role of hormonal therapy is poorly defined in the management of these tumours.
  • Herein regression of choroidal metastasis from primary breast carcinoma following antihormonal therapy with the antioestrogen drug Letrozole is reported.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Choroid Neoplasms / drug therapy. Estrogen Receptor Modulators / therapeutic use. Nitriles / therapeutic use. Triazoles / therapeutic use
  • [MeSH-minor] Adult. Female. Fluorescein Angiography. Humans. Remission Induction. Tomography, Optical Coherence

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17651258.001).
  • [ISSN] 1442-6404
  • [Journal-full-title] Clinical & experimental ophthalmology
  • [ISO-abbreviation] Clin. Experiment. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Estrogen Receptor Modulators; 0 / Nitriles; 0 / Triazoles; 7LKK855W8I / letrozole
  •  go-up   go-down


14. Bechrakis NE, Scheibenbogen C, Schmittel A, Servetopoulou F, Foerster MH, Keilholz U: [Choroid melanoma. Adjuvant therapy in high risk patients and new therapy approaches in the metastatic stage]. Ophthalmologe; 2002 May;99(5):333-7
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Choroid melanoma. Adjuvant therapy in high risk patients and new therapy approaches in the metastatic stage].
  • [Transliterated title] Aderhautmelanom. Adjuvante Therapie bei Hochrisikopatienten und neue Therapieansätze im metastasierten Stadium.
  • The treatment modality of primary uveal melanoma has up to now had no direct influence on the evolution of metastatic disease.
  • Novel adjuvant treatment modalities are being developed on the basis of identifying significant prognostic factors for survival.
  • The development of vaccination protocols targeting specific melanoma and/or tumor antigens has gained increasing importance and is currently being evaluated.
  • In the last years median survival of selected patients with metastatic disease could be increased to 14 months by intrahepatic fotemustin influsions.
  • Novel systemic chemotherapy protocols are currently being evaluated based on chemosensitivity studies.
  • Furthermore, immunotherapeutical modalities are entering clinical evaluation as treatment for metastatic uveal melanoma.
  • [MeSH-major] Choroid Neoplasms / therapy. Melanoma / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Liver Neoplasms / mortality. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Neoplasm Staging. Palliative Care. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12043286.001).
  • [ISSN] 0941-293X
  • [Journal-full-title] Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
  • [ISO-abbreviation] Ophthalmologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 30
  •  go-up   go-down


15. Schmidt D, Ness T, Geissler M: Cotton-wool spots associated with pancreatic carcinoma. Eur J Med Res; 2001 Mar 26;6(3):101-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Malignant tumors of different organs may cause changes in the eye.
  • In addition, the man revealed a metastasis of the choroid in the right eye.
  • The cotton-wool spots were reduced in size in the woman after treatment with Gemcitabine.
  • After termination of treatment, their general condition deteriorated and they died within a few weeks.
  • [MeSH-minor] Adrenal Gland Neoplasms / drug therapy. Adrenal Gland Neoplasms / secondary. Biomarkers, Tumor / metabolism. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Eye Neoplasms / diagnosis. Eye Neoplasms / drug therapy. Eye Neoplasms / secondary. Fatal Outcome. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lymphatic Metastasis / pathology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11309222.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


16. Shields JA, Perez N, Shields CL, Singh AD, Eagle RC Jr: Orbital melanoma metastatic from contralateral choroid: management by complete surgical resection. Ophthalmic Surg Lasers; 2002 Sep-Oct;33(5):416-20
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for orbital melanoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital melanoma metastatic from contralateral choroid: management by complete surgical resection.
  • We discuss a clinicopathologic correlation of orbital metastasis from a contralateral choroidal melanoma wherein the orbital tumor was removed completely by surgical resection.
  • In October 1982, a 29-year-old woman was treated with cobalt-60 plaque radiotherapy for a choroidal melanoma in her right eye.
  • The tumor responded well but recurred after 9 years, necessitating enucleation.
  • In August 1999, 17 years after initial presentation, metastatic melanoma to liver, lung, and brain were found and the patient had a favorable response to chemotherapy and brain irradiation.
  • Complete surgical removal of the tumor was achieved by a superotemporal orbitotomy.
  • Histopathologically, the tumor was a malignant melanoma with features similar to the choroidal tumor.
  • The contralateral orbit can be the site of late metastasis from choroidal melanoma.
  • In rare instances, an orbital metastasis can be completely removed surgically without subjecting the patient to orbital irradiation.
  • [MeSH-major] Choroid Neoplasms / pathology. Melanoma / secondary. Orbital Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12358296.001).
  • [ISSN] 1082-3069
  • [Journal-full-title] Ophthalmic surgery and lasers
  • [ISO-abbreviation] Ophthalmic Surg Lasers
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


17. Donovan DJ, Prauner RD: Shunt-related abdominal metastases in a child with choroid plexus carcinoma: case report. Neurosurgery; 2005 Feb;56(2):E412; discussion E412
Genetic Alliance. consumer health - Choroid Plexus Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shunt-related abdominal metastases in a child with choroid plexus carcinoma: case report.
  • OBJECTIVE AND IMPORTANCE: Metastasis of primary brain neoplasms to the abdomen through a ventriculoperitoneal shunt (VPS) has been described for many types of tumors, including medulloblastoma, germ cell tumors, astrocytoma, oligodendroglioma, lymphoma, ependymoma, and melanoma.
  • Choroid plexus tumors (CPTs) are located within the cerebrospinal fluid-containing spaces of the brain and frequently disseminate throughout the craniospinal subarachnoid space, yet VPS-related metastasis of a CPT to the abdomen has not been reported previously.
  • CLINICAL PRESENTATION: We present the case of a 3-year-old boy with choroid plexus carcinoma of the lateral ventricle and preoperative intraventricular dissemination of the tumor.
  • The patient later developed VPS-related abdominal metastases causing abdominal ascites.
  • INTERVENTION: Surgical resection of the tumor was followed by chemotherapy and craniospinal radiation, but the tumor further disseminated throughout the craniospinal subarachnoid space.
  • When the child presented with abdominal ascites, the distal VPS catheter was externalized and drained cerebrospinal fluid at a rate of more than 750 ml/d.
  • Paracentesis was performed for persistent ascites, and cytological analysis of the fluid revealed metastatic tumor cells.
  • CONCLUSION: The child died from widely metastatic tumor and aspiration pneumonia.
  • CPT metastasis to the abdomen through a VPS should be considered in patients with the appropriate clinical findings.
  • This condition may exacerbate overproduction of cerebrospinal fluid, which can occur with CPTs, and treatment must be individualized.
  • [MeSH-major] Abdominal Neoplasms / etiology. Abdominal Neoplasms / secondary. Carcinoma / etiology. Carcinoma / secondary. Choroid Plexus Neoplasms / pathology. Ventriculoperitoneal Shunt / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670391.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Lederman M, Meir T, Zeschnigk M, Pe'er J, Chowers I: Inhibitor of apoptosis proteins gene expression and its correlation with prognostic factors in primary and metastatic uveal melanoma. Curr Eye Res; 2008 Oct;33(10):876-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitor of apoptosis proteins gene expression and its correlation with prognostic factors in primary and metastatic uveal melanoma.
  • PURPOSE: Members of the inhibitors of apoptosis proteins (IAPs) family are thought to promote tumor growth and interfere with response to therapy by suppressing apoptosis in several malignancies.
  • We aimed to evaluate the expression of IAPs in uveal melanoma (UM) and its correlation with prognostic factors associated with death from metastatic UM.
  • QPCR results were correlated with apoptosis rate and with prognostic factors in UM, including lesion dimensions, cell type, monosomy 3, and vascular mimicry patterns.
  • RESULTS: IAP genes were expressed in the majority of primary and metastatic UM.
  • BIRC5 and BIRC7 levels were 8.8-fold (p = 0.0003) and 7.0-fold (p = 0.003) higher in tumors (primary and metastatic tissue) vs. normal eye tissue, respectively.
  • BIRC5 levels correlated with presence of monosomy 3 (p = 0.01) and higher levels of BIRC7 correlated with epithelioid cell type (p = 0.048).
  • Considering our findings together with previous reports on their role in a variety of malignancies and in UM cell lines, it is conceivable that IAPs contribute to the remarkable resistance of uveal melanoma to apoptosis-inducing chemotherapy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis / genetics. Cell Line, Tumor. Choroid / metabolism. Chromosome Aberrations. Chromosomes, Human, Pair 3 / genetics. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Retina / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18853322.001).
  • [ISSN] 1460-2202
  • [Journal-full-title] Current eye research
  • [ISO-abbreviation] Curr. Eye Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Inhibitor of Apoptosis Proteins
  •  go-up   go-down


19. Soysal HG: Metastatic tumors of the uvea in 38 eyes. Can J Ophthalmol; 2007 Dec;42(6):832-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic tumors of the uvea in 38 eyes.
  • BACKGROUND: The reported incidence of metastatic uveal tumors has been increasing.
  • The aim of this study is to report the clinical features, management, and prognosis of uveal metastatic tumors seen in a general oncology hospital.
  • METHODS: The records of 28 patients with uveal metastasis diagnosed between 1999 and 2006 were reviewed retrospectively.
  • RESULTS: Uveal metastatic tumours were detected in a total of 38 eyes, uveal involvement included the iris in 4 eyes and the choroid in 37 eyes.
  • The primary cancer site was the breast in 24 patients, the lung in 2 patients, the ovary in 1 patient, and the gastrointestinal tract in 1 patient.
  • Choroidal metastases typically were creamy yellow in color, plateau or dome-shaped, and associated with secondary retinal detachment in 56.8% of eyes.
  • The mean time interval between ocular and systemic diagnosis was 41.07 months.
  • At the time of ocular diagnosis, 75% of patients had systemic metastasis.
  • Eight eyes were treated with chemotherapy and hormone therapy, and external beam radiotherapy was applied to 30 eyes.
  • Lesions commonly responded well to therapy, but 22 patients died as a result of disseminated systemic disease.
  • INTERPRETATION: Patients with uveal metastasis generally present to ophthalmologists with visual symptoms but may be asymptomatic in some cases.
  • Local tumor control can be managed with current therapy, but systemic prognosis is generally poor because of the disseminated stage of the malignant disease.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17985001.001).
  • [ISSN] 0008-4182
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


20. De Potter P: Current treatment of retinoblastoma. Curr Opin Ophthalmol; 2002 Oct;13(5):331-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current treatment of retinoblastoma.
  • Chemotherapy has recently achieved a major role in the primary management of intraocular retinoblastoma.
  • Tumor reduction by first-line chemotherapy (chemoreduction) followed by local treatments is now accepted as treatment strategy for intraocular retinoblastoma with the goal of avoiding external beam radiotherapy (EBRT) or enucleation.
  • Although efficient in reducing tumor volume, chemotherapy cannot cure retinoblastoma.
  • Different chemoreduction protocols are used to shrink the tumor, making it treatable with cryotherapy, laser photocoagulation, thermotherapy, and plaque radiotherapy.
  • Systemic chemotherapy used with local ophthalmic therapies during or after the chemotherapy can eliminate the need for enucleation or external beam radiotherapy in Reese-Ellsworth group 1, 2, or 3 retinoblastoma.
  • This combination is not sufficient to obtain tumor control in most eyes with large tumors and diffuse vitreous and subretinal seeds (Reese-Ellsworth group 4 and 5 tumors), and EBRT or enucleation is eventually required.
  • The resultant visual acuity after globe-conserving therapies in those eyes with Reese-Ellsworth group 4 and 5 tumors is often poor.
  • Enucleation is still recommended in situations such as eyes containing large tumors, long standing retinal detachment, neovascular glaucoma, pars plana tumor seeding, anterior chamber involvement or choroid, optic nerve or orbital tumor extension, and no expectation for useful vision.
  • Chemoprophylaxis is necessary for patients with tumor extending to the surgical margin of the optic nerve and is likely beneficial in preventing metastases in patients with tumor extending beyond the lamina cribrosa.
  • Intensified chemotherapy with autologous stem cell rescue appears effective for patients with metastatic retinoblastoma.
  • [MeSH-major] Retinal Neoplasms / therapy. Retinoblastoma / therapy
  • [MeSH-minor] Brachytherapy. Combined Modality Therapy. Cryotherapy. Drug Therapy. Eye Enucleation. Humans. Laser Coagulation

  • Genetic Alliance. consumer health - Retinoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12218465.001).
  • [ISSN] 1040-8738
  • [Journal-full-title] Current opinion in ophthalmology
  • [ISO-abbreviation] Curr Opin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


21. Akahira J, Konno R, Ito K, Sato S, Yajima A: Choroidal metastasis presented as the initial symptom of the recurrence from ovarian endometrioid adenocarcinoma: A case report. Gynecol Oncol; 2000 Apr;77(1):219-21
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroidal metastasis presented as the initial symptom of the recurrence from ovarian endometrioid adenocarcinoma: A case report.
  • Choroidal metastasis from recurrent ovarian cancer is extremely rare.
  • Ophthalmologic evaluation revealed a metastatic choroidal tumor from ovarian cancer which had been diagnosed 10 years ago.
  • After cesarean section, multiple metastases were found including the choroid, scalp, bone, and lung, and she received four courses of single agent carboplatin chemotherapy.
  • This case highlights the need to investigate the etiology of visual complaints in patients with a history of ovarian cancer even in the early stage.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Choroid Neoplasms / secondary. Ovarian Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Neoplasm Metastasis / diagnosis. Neoplasm Recurrence, Local. Pregnancy. Vision Disorders / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 10739718.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


22. Bedikian AY, Plager C, Papadopoulos N, Ellerhorst J, Smith T, Benjamin RS: A phase II evaluation of bexarotene (Targretin) capsules in patients with metastatic melanoma. Oncol Rep; 2000 Jul-Aug;7(4):883-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II evaluation of bexarotene (Targretin) capsules in patients with metastatic melanoma.
  • Nineteen patients, four with choroidal metastatic melanoma, were treated.
  • Five patients had stable disease, two of the four with choroidal melanoma, had tumor progression.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Choroid Neoplasms / drug therapy. Conjunctival Neoplasms / drug therapy. Melanoma / drug therapy. Skin Neoplasms / drug therapy. Tetrahydronaphthalenes / therapeutic use
  • [MeSH-minor] Adult. Capsules. Female. Humans. Lymphatic Metastasis. Male. Neoplasm Metastasis. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10854563.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Capsules; 0 / Tetrahydronaphthalenes; A61RXM4375 / bexarotene
  •  go-up   go-down


23. Shields JA, Shields CL, Brotman HK, Carvalho C, Perez N, Eagle RC Jr: Cancer metastatic to the orbit: the 2000 Robert M. Curts Lecture. Ophthal Plast Reconstr Surg; 2001 Sep;17(5):346-54
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer metastatic to the orbit: the 2000 Robert M. Curts Lecture.
  • PURPOSE: To report the demographics and clinical features of a large series of patients with orbital metastasis.
  • METHODS: Retrospective chart review on 100 consecutive patients and a literature review on orbital metastasis.
  • RESULTS: Of 100 patients, the primary tumor site was breast in 53 (53%), prostate gland in 12 (12%), lung in 8 (8%), skin (melanoma) in 6 (6%), kidney in 5 (5%), gastrointestinal tract in 5 (5%), choroid (melanoma) in 2 (2%), parotid gland in 1 (1%), and adrenal gland (neuroblastoma) in 1 (1%).
  • Of patients in whom a detailed history was available, there was no history of cancer at the time of presentation in 19%.
  • In 10%, the primary tumor remained undetected despite systemic evaluation.
  • There were 36 male patients and 64 female patients whose mean age at diagnosis was 62 years (median 60 years, range 5 to 91 years).
  • Treatment included chemotherapy, hormone therapy, irradiation, surgical excision, or observation, depending on clinical circumstances.
  • Among patients with sufficient follow-up, 95% died of metastasis, with overall mean survival of 15 months (median 15 months; range 3 to 96 months) after orbital diagnosis.
  • CONCLUSIONS: The most common primary cancers that metastasize to the orbit are breast, prostate gland, and lung cancer.
  • In 19%, there is no history of cancer when the patient presents with ophthalmic symptoms and in 10% the primary site remains obscure despite systemic evaluation.
  • [MeSH-major] Carcinoma / secondary. Melanoma / secondary. Neoplasms / pathology. Neuroblastoma / secondary. Orbital Neoplasms / secondary. Sarcoma / secondary
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Tomography, X-Ray Computed


24. Chen J, Balmaceda C, Bruce JN, Sisti MB, Huang M, Cheung YK, McKhann GM, Goodman RR, Fine RL: Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients. J Neurooncol; 2006 Jan;76(1):85-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients.
  • BACKGROUND: P-glycoprotein (Pgp) mediates, in part, resistance to natural product chemotherapy drugs which constitute over half of the available drugs for cancer treatment.
  • Tamoxifen (TAM) enhances intracellular deposition of natural product chemotherapy in human cell lines by inhibition of Pgp.
  • Pgp is highly expressed in the choroid plexus and is thought to be a key component of the blood-cerebrospinal fluid barrier (BCSFB).
  • METHODS: Ten patients with either primary or metastatic brain tumors were randomized to: paclitaxel alone (175 mg/m2/IV) or a course of TAM (160 mg/m2 PO BID on Days 1-5) followed by paclitaxel (175 mg/m2/IV on Day 5).
  • CONCLUSIONS: The trend towards lower paclitaxel CSF concentrations when given with TAM is consistent with the published finding that Pgp's localization in the endothelial cells of the choroid plexus works in an opposite direction and keeps drugs in the CSF.
  • Thus, agents which inhibit Pgp, such as TAM, may increase efflux of Pgp substrates out of the BCSFB and may paradoxically lower CSF concentrations of natural product chemotherapy drugs.
  • [MeSH-major] Antineoplastic Agents, Hormonal / pharmacology. Antineoplastic Agents, Phytogenic / cerebrospinal fluid. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Paclitaxel / cerebrospinal fluid. Tamoxifen / pharmacology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Feb 1;93(3):787-95 [9920827.001]
  • [Cites] J Chromatogr. 1992 Nov 6;582(1-2):273-8 [1362729.001]
  • [Cites] Oncol Rep. 2002 Jul-Aug;9(4):683-8 [12066192.001]
  • [Cites] Blood. 1991 Feb 15;77(4):818-25 [1993221.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] Clin Cancer Res. 1996 Apr;2(4):619-22 [9816211.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):1022-30 [9041166.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):2964-76 [9738565.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3900-5 [10097135.001]
  • [Cites] J Clin Oncol. 1992 Oct;10(10):1635-42 [1403041.001]
  • [Cites] Biochem Pharmacol. 1998 Feb 15;55(4):523-31 [9514088.001]
  • [Cites] J Natl Cancer Inst. 1995 Jul 19;87(14):1077-81 [7616600.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):1955-60 [9951847.001]
  • [Cites] Neuro Oncol. 1999 Apr;1(2):101-8 [11550305.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jan;86(2):695-8 [2563168.001]
  • [Cites] Biochem Pharmacol. 1994 Jul 19;48(2):287-92 [7914405.001]
  • [Cites] Arch Neurol. 1999 Jun;56(6):703-8 [10369310.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Jul 15;202(1):606-12 [7913604.001]
  • [Cites] J Chromatogr. 1991 Apr 19;565(1-2):482-7 [1831461.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2188-94 [9626220.001]
  • [Cites] Br J Clin Pharmacol. 1997 Feb;43(2):189-93 [9131952.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 2;84(23):1811-6 [1359155.001]
  • [Cites] Br J Cancer. 1991 Apr;63(4):641-5 [2021551.001]
  • (PMID = 16402278.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA089395
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 0 / P-Glycoprotein; 094ZI81Y45 / Tamoxifen; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


25. Read RW, Green RL, Rao NA: Metastatic adenocarcinoma with rupture through the Bruch membrane simulating a choroidal melanoma. Am J Ophthalmol; 2001 Dec;132(6):943-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma with rupture through the Bruch membrane simulating a choroidal melanoma.
  • PURPOSE: To report a case of adenocarcinoma metastatic to the choroid with rupture through the Bruch membrane, thus, simulating a choroidal melanoma.
  • RESULTS: A 62-year-old Hispanic female presented with visual loss, right eye, of short duration because of a choroidal mass with retinal detachment.
  • Ultrasonography showed a dome-shaped lesion with an eccentric collar-button projection and medium internal reflectivity, which suggested a choroidal melanoma.
  • Severe pain necessitated enucleation, RE, and histopathology of the choroidal mass demonstrated an adenocarcinoma.
  • CONCLUSION: Metastatic choroidal tumors may present, although rarely, with collar-button configurations.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / pathology. Bruch Membrane / pathology. Choroid Neoplasms / secondary. Melanoma / diagnosis. Retinal Detachment / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / drug therapy. Diagnosis, Differential. Eye Enucleation. Female. Fluorescein Angiography. Humans. Immunoenzyme Techniques. Lung Neoplasms / diagnosis. Lung Neoplasms / drug therapy. Middle Aged. Pain / diagnosis. Rupture, Spontaneous

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Retinal Detachment.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11730672.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


26. Amer R, Pe'er J, Chowers I, Anteby I: Treatment options in the management of choroidal metastases. Ophthalmologica; 2004 Nov-Dec;218(6):372-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment options in the management of choroidal metastases.
  • We performed a retrospective study of 40 consecutive patients (50 eyes) treated for choroidal metastases of solid systemic malignancies in order to evaluate treatment results.
  • Patients received either systemic or local therapy or a combination of both.
  • The most common primary tumor was breast carcinoma (62.5%).
  • Systemic chemotherapy alone was used in 13.3% of eyes, local therapy alone in 44.4%, and a combination of both in 42.2% of eyes.
  • Local treatment modalities included brachytherapy, external beam irradiation, and laser photocoagulation.
  • Complete regression of the choroidal metastases was seen in 57.8% of eyes, partial regression in 15.6 and no response in 4.4%; 22.2% were not available for re-evaluation.
  • We have concluded that the treatment modality in patients with metastatic ocular disease should be individually tailored.
  • When ocular metastases are concurrent with widespread metastatic disease, systemic chemotherapy alone or in combination with local therapy is reasonable.
  • In patients manifesting metastases in the eyes alone, local therapy modalities may be safe, allowing conservation of visual functions with minimal systemic morbidity.
  • [MeSH-major] Choroid Neoplasms / secondary. Choroid Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Brachytherapy. Combined Modality Therapy. Female. Humans. Laser Coagulation. Male. Middle Aged. Neoplasms / pathology. Neoplasms / therapy. Retrospective Studies. Visual Acuity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 S. Karger AG, Basel.
  • (PMID = 15564754.001).
  • [ISSN] 0030-3755
  • [Journal-full-title] Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde
  • [ISO-abbreviation] Ophthalmologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


27. Holland D, Maune S, Kovács G, Behrendt S: Metastatic tumors of the orbit: a retrospective study. Orbit; 2003 Mar;22(1):15-24

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic tumors of the orbit: a retrospective study.
  • PURPOSE: To present the clinical features and facts on prognosis, therapy and diagnostics of orbital metastases treated in the Orbital Center Kiel.
  • On average, 64 months was the period of time between the onset of the primary disease and orbital manifestation.
  • The sites of the primary tumors were breast (8), choroid (2), prostate (2), gastrointestinal tract (3), lung (2), urinary bladder (1), Schmincke tumor of the throat (1) and unknown origin (1).
  • Although the majority (16/20) were treated by chemotherapy, radiotherapy or surgery, 19 patients died after a mean survival time of 14.7 months.
  • CONCLUSION: Orbital metastases remain an unfavorable prognostic factor, but the diagnosis and treatment are still important in order to prevent loss of vision and improve the patient's quality of life.
  • [MeSH-major] Orbital Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Prognosis. Quality of Life. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12759863.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


28. Tazi N, Le Thi Huong D, Bodaghi B, Rixe O, Lehoang P, Piette JC: [Choroidal metastasis revealing pulmonary adenocarcinoma]. Rev Med Interne; 2006 Sep;27(9):699-701
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Choroidal metastasis revealing pulmonary adenocarcinoma].
  • Lung cancer is the first cause of choroidal metastasis in man.
  • He presented with visual decrease and metamorphopsia that lead to the diagnosis of a metastatic adenocarcinoma of the lung (bone, liver, choroid, nodles).
  • Chemotherapy permitted to improve visual acuity, in parallel with disappearance of choroidal metatasis.
  • Discovery of choroidal tumor should evoke in first line metastasis.
  • Chemotherapy can improve visual acuity and the quality of life.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16872723.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


29. Cormio G, Martino R, Loizzi V, Resta L, Selvaggi L: A rare case of choroidal metastasis presented after conservative management of endometrial cancer. Int J Gynecol Cancer; 2006 Nov-Dec;16(6):2044-8
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of choroidal metastasis presented after conservative management of endometrial cancer.
  • Hematogenous dissemination from endometrial cancer is quite rare.
  • We report a 31-year-old woman who developed choroidal metastasis following conservative management of early-stage endometrial carcinoma.
  • Three years after hysterectomy for persistent endometrial carcinoma, she developed multiple metastatic disease (to both lungs and right pelvis), and while on treatment with paclitaxel and carboplatin, she complained of a rapid visual deterioration.
  • Ophthalmologic evaluation revealed a metastatic choroidal tumor associated with multiple central nervous system metastases.
  • The patient refused further treatment and died 1 month after diagnosis of choroidal involvement.
  • In conclusion, this is the first reported case of choroidal metastasis from endometrial cancer and highlights the need to consider immunosuppressive treatment as an absolute contraindication to conservative fertility-sparing treatment in gynecological malignancies.
  • [MeSH-major] Choroid Neoplasms / pathology. Choroid Neoplasms / secondary. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Prednisone / therapeutic use

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17177844.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] VB0R961HZT / Prednisone
  •  go-up   go-down


30. Kociecki J, Biczysko W, Alugail AW: [Secondary retinal detachment accompanying intraocular tumors]. Klin Oczna; 2004;106(1-2):39-44
MedlinePlus Health Information. consumer health - Retinal Detachment.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Secondary retinal detachment accompanying intraocular tumors].
  • PURPOSE: Aim of the study--the attempt to answer, what is the present incidence mechanism of arising, and what parameters can influence the development of secondary retinal detachment (s. r. d.) caused by intraocular choroidal tumor.
  • MATERIAL AND METHOD: 107 eyes of 105 consecutive patients aged 21 to 82 years (mean 62 years), diagnosed clinically as having choroidal malignant tumor, were evaluated.
  • The cause of s. r. d. was primary malignant choroidal tumor and in 3 cases--metastatic tumor.
  • The therapy included brachytherapy, diode laser transpupillary thermotherapy (TTT), chemotherapy, local tumor excision and combined treatment.
  • After therapy the detachment conceded in 10 eyes (37%).
  • 4. In case of large tumors the detachment has mainly "mechanical" character, however it may be also influenced by increased permeability of tumor vessels and impaired function of retinal pigment epithelium; the latter mechanism seems to play the main role in case of small tumors; in both cases the external retinal layer is damaged.
  • 5. The most common cause of s. r. d. are tumors located in posterior pole (45%) and least frequently in upper-temporal quadrant (7%).
  • 6. After brachytherapy, TTT or local tumor excision in selected cases s. r. d. may totally regress.
  • [MeSH-major] Choroid Neoplasms / complications. Retina / pathology. Retinal Detachment / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Incidence. Male. Middle Aged. Poland / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15218763.001).
  • [ISSN] 0023-2157
  • [Journal-full-title] Klinika oczna
  • [ISO-abbreviation] Klin Oczna
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


31. Shields CL, Honavar S, Shields JA, Demirci H, Meadows AT: Vitrectomy in eyes with unsuspected retinoblastoma. Ophthalmology; 2000 Dec;107(12):2250-5
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MAIN OUTCOME MEASURES: The two main outcome measures were ultimate patient management and the development of retinoblastoma metastasis.
  • RESULTS: Of more than 900 consecutive patients with retinoblastoma managed on the Ocular Oncology Service at Wills Eye Hospital in Philadelphia, 11 (1%) had prior vitrectomy in an eye with viable tumor before referral to us for suspected retinoblastoma.
  • Anterior chamber tumor cells were clinically visible in four eyes (36%), hyphema in two eyes (18%), and iris neovascularization in two eyes (18%).
  • Adjuvant treatment was delivered in 10 patients (91%), using orbital radiotherapy in nine patients (82%) and chemotherapy in nine patients (82%).
  • Histopathologic evidence of retinoblastoma invasion was documented in the episclera (two eyes; 18%), anterior chamber (seven eyes; 64%), iris (five eyes; 45%), ciliary body (five eyes; 45%), choroid (three eyes; 27%), and optic nerve (four eyes; 36%; prelaminar, two eyes; postlaminar, two eyes).
  • The vitrectomy ports, Tenon's fascia, cut end of the optic nerve, and orbit were free of tumor.
  • Of the 10 patients who received prophylactic chemotherapy, radiotherapy, or both in addition to enucleation for prevention of retinoblastoma metastasis, none (0%) experienced metastasis or orbital recurrence during the mean follow-up of 7 years (range, 0.2-24 years) from the time of retinoblastoma diagnosis.
  • However, one patient was referred to us after the development of metastatic retinoblastoma, and despite aggressive chemotherapy and radiotherapy after enucleation, died 24 months later.
  • If vitrectomy is performed in an eye with unsuspected retinoblastoma, enucleation combined with adjuvant chemotherapy, radiotherapy, or both without delay is advised to prevent systemic tumor dissemination.
  • [MeSH-major] Retinal Neoplasms / diagnosis. Retinoblastoma / diagnosis. Vitrectomy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Endophthalmitis / surgery. Eye Enucleation. Eye Infections, Parasitic / surgery. Female. Humans. Male. Neoplasm Invasiveness. Prognosis. Retrospective Studies. Vitreous Hemorrhage / surgery

  • Genetic Alliance. consumer health - Retinoblastoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11097606.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  •  go-up   go-down


32. Djukić VB, Kastratović DA, Pendjer IP, Majstorović BM, Nikolić LjI, Boricić IV, Vujicić ZN: Patient with double cancer--successfully treated. Acta Chir Iugosl; 2005;52(3):91-3
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient with double cancer--successfully treated.
  • INTRODUCTION: Etiology of thrombosis in malignant diseases is multifactorial, and mechanisms that lead to thrombosis include release of the procoagulants from tumor cells (PC), factor related to bed rest, infections, as well as oncological therapy --chemotherapy, hormones, radiotherapy and surgical treatment.
  • CASE REPORT: 53 years old female patient hospitalised because of hypopharingeal cancer with metastasis in the left neck.
  • Persistent thrombocitosis in laboratory monitoring indicated more adequate diagnostic procedures, which led to discovering of Chorioidal Malignant Mellanoma as a second cancer.
  • Patient was discharged from the hospital in good health condition, free of any other symptom of the malignant disease.
  • We suggest anticoagulants to prevent thromboembolic complications, affect the angiogenesis and prevent development of metastatic disease.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Choroid Neoplasms / therapy. Melanoma / therapy. Neoplasms, Multiple Primary / therapy. Tongue Neoplasms / therapy
  • [MeSH-minor] Female. Humans. Lymphatic Metastasis. Middle Aged. Venous Thrombosis / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16813002.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


33. Schniederjan MJ, Shehata B, Brat DJ, Esiashvili N, Janss AJ: De novo germline TP53 mutation presenting with synchronous malignancies of the central nervous system. Pediatr Blood Cancer; 2009 Dec 15;53(7):1352-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De novo germline TP53 mutation presenting with synchronous malignancies of the central nervous system.
  • We present a case of a 14-year-old male with a germline TP53 mutation who presented with synchronous primitive neuroectodermal tumor and choroid plexus carcinoma.
  • Within 5 months of presentation, the child developed widely metastatic alveolar rhabdomyosarcoma.
  • This case identifies a rare, de novo, germline TP53 mutation presenting with synchronous CNS malignancies and exhibiting a more fulminant course than typical cases of Li-Fraumeni syndrome.
  • [MeSH-major] Brain Neoplasms / genetics. Carcinoma / genetics. Choroid Plexus Neoplasms / genetics. Codon, Nonsense. Genes, p53. Germ-Line Mutation. Neoplasms, Multiple Primary / genetics. Neuroectodermal Tumors, Primitive / genetics. Rhabdomyosarcoma, Alveolar / genetics. Rhabdomyosarcoma, Alveolar / secondary
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Cranial Irradiation. Fatal Outcome. Frontal Lobe / pathology. Frontal Lobe / surgery. Humans. Lomustine / administration & dosage. Male. Neoplasms, Unknown Primary / genetics. Radiotherapy, Adjuvant. Spinal Neoplasms / drug therapy. Spinal Neoplasms / radiotherapy. Spinal Neoplasms / secondary. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19711436.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon, Nonsense; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement